American Society of Hematology

Potential Sickle Cell Cure Targets BCL11A

December 11, 2019

Article

In a 3-patient study presented at ASH, investigators believe they have found a therapeutic target to cure sickle cell disease.

ASH Data Points to Correlation Between Biomarkers and Sickle Cell Outcomes

December 11, 2019

Article

In a study presented at the annual ASH meeting, investigators link biomarkers of cardiopulmonary, renal, and liver dysfunction with specific outcomes for adult sickle cell disease patients.

Navitoclax/Ruxolitinib Combination Improves Outcomes for Patients With Myelofibrosis

December 11, 2019

Article

Results of a recent study from ASH 2019 is suggesting a combination of navitoclax and ruxolitinib could improve outcomes for patients with myelofibrosis.

Adding Daratumumab to Myeloma Treatment Reduces Risk of Progression, Death

December 10, 2019

Article

Carfilzomib, dexamethasone, and daratumumab can be a good regimen for relapsed or refractory multiple myeloma, investigators found.

CC-486 Could Represent New Therapeutic Standard for AML Patients

December 10, 2019

Article

Results of a phase 3 study presented during the late-breaking sessions at ASH 2019 has found CC-486 provided patients with significant and meaningful improvements in overall survival (OS) and relapse-free survival.

Sutimlimab Improves Hemoglobin in Cold Agglutinin Disease

December 10, 2019

Article

The investigative monoclonal antibody may become the first therapy indicated for the rare autoimmune disease.

Blinatumomab Outperforms Chemo in Children, Young Adults with B-ALL

December 10, 2019

Article

Results of a phase 3 study presented at ASH 2019 are suggesting blinatumomab was more effective than chemotherapy as a post-reinduction therapy in high and intermediate risk first relapse of b-acute lymphoblastic leukemia.

Bispecific CAR-T Cell Therapy Shows Promise Treating RRMM

December 10, 2019

Article

During the annual ASH meeting, investigators present phase 1 data from a new dose-climbing trial.

Autologous Stem Cell Transplants Are Safe for Older Multiple Myeloma Patients

December 10, 2019

Article

More patients with multiple myeloma could benefit from autologous hematopoietic cell transplantation, investigators found.

Novel Agent Shows Early Promise for Advanced Myelofibrosis

December 10, 2019

Article

Results of the phase 2 MANIFEST study presented at ASH 2019 suggest CPI-0610 could be an effective treatment for patients with refractory or intolerant advanced myelofibrosis.

x